LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Akcijų sąrašas・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Uždarymo kaina

SektoriusSveikatos priežiūra

54.89 0.96

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

54.31

Max

55.05

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.6B 2.7B
Pardavimai	-1B 11B
P/E Sektoriaus vid.	15.392 49.888
Pelnas, tenkantis vienai akcijai	1.31
Dividendų pajamingumas	4.37
Pelno marža	23.309
Darbuotojai	32,500
EBITDA	1.5B 3.7B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+16.25% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	4.37% 2.38%
Kitas uždarbis	2026-07-30
Kitas dividendų mokėjimo data	2026-07-31
Kita Ex Dividend data	2026-07-02

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-5.8B 112B
Ankstesnė atidarymo kaina	53.93
Ankstesnė uždarymo kaina	54.89

Bristol-Myers Squibb Co. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-03 13:08; UTC

Uždarbis

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

2026-05-12 06:42; UTC

Pagrindinės rinkos jėgos

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

2026-04-30 11:14; UTC

Uždarbis

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

2026-05-29 08:15; UTC

Rinkos pokalbiai

Uždarbis

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

2026-05-05 18:12; UTC

Uždarbis

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026-05-05 13:54; UTC

Uždarbis

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Rev $11.49B >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q EPS $1.31 >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

2026-04-30 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

2026-04-14 14:13; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 12:57; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 11:19; UTC

Uždarbis

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

2026-04-14 10:34; UTC

Uždarbis

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

2026-04-13 21:23; UTC

Uždarbis

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Bristol-Myers Squibb Co. Prognozė

Kainos tikslas

By TipRanks

16.25% į viršų

12 mėnesių prognozė

Vidutinis 63.31 USD 16.25%

Aukščiausias 75 USD

Žemiausias 40 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Bristol-Myers Squibb Co. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

20 ratings

Pirkti

Laikyti

Parduoti

Remiantis 20 analitikų, pateikusių Bristol-Myers Squibb Co. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.